Nuclear Cardiology

Single photon computed tomography (SPECT) and positron emission tomography (PET) molecular imaging are used as primary cardiac imaging modalities to evaluate the function of the heart. It uses radioactive isotopes attached to sugars that are metabolized by cardiomyocytes. This creates an image of the metabolic activity of the heart and shows areas of ischemia or infarct. Other radiotracers can image the heart to diagnosis cardiac amyloidosis and sarcoidosis. 

RSS icon
Thumbnail

Combining AI with cardiac imaging helps predict heart attacks, cardiovascular deaths

The findings were presented virtually during the Society of Nuclear Medicine and Molecular Imaging's 2021 Annual Meeting.

Thumbnail

Imaging advocates offer guidance after reported spate of SPECT/CT payment denials

The Society of Nuclear Medicine & Molecular Imaging said it’s received “many complaints” from the field pertaining to various commercial payers. 

Humana

Humana agrees to take second look at panned payment change labeling PET/CT as ‘investigational’

The American Society of Nuclear Cardiology recently met with the Louisville, Kentucky, insurer, which shared an openness to reviewing a recent coverage determination. 

M&A mergers and acquisitions business deal

Medical imaging isotope producer Shine finalizes merger with fusion technology specialist

With the help of Phoenix's advanced industrial imaging capabilities, the new entity hopes to ramp up its production of molybdenum-99.

chest pain lung pulmonary embolism

CCTA is a safe, effective alternative to SPECT in patients with stable chest pain

The findings come by way of the RESCUE Trial, which included more than 1,000 participants from 44 different sites.

insurance payer payment insurer

Top nuclear imaging group ‘strongly disagrees’ with Humana’s decision to refuse coverage for PET/CT

The Society of Nuclear Medicine and Molecular Imaging said the move denies patients access to potentially lifesaving technologies.

Attralus completes financing to validate pan-amyloid nuclear imaging agent

Biopharmaceutical firm Attralus has completed a $25 million Series A financing designed to further validate its AT-01 pan-amyloid radiotracer for PET/CT.

Thumbnail

SNMMI 2020: Imaging highlights connection between heart and kidneys in heart attack response

Researchers monitored how the heart and kidneys responded one day, three days, seven days and six weeks following an induced myocardial infarction. 

Displaying 81 - 88 of 100
Design by Adaptive Theme